The estimated Net Worth of Eddie Williams is at least $19.4 Thousand dollars as of 4 March 2020. Eddie Williams owns over 2,000 units of BioAtla stock worth over $19,402 and over the last 7 years Eddie sold BCAB stock worth over $0.
Sign up
Eddie Williams BCAB stock SEC Form 4 insiders trading
Eddie has made over 1 trades of the BioAtla stock since 2020, according to the Form 4 filled with the SEC. Most recently Eddie bought 2,000 units of BCAB stock worth $11,560 on 4 March 2020.
The largest trade Eddie's ever made was buying 2,000 units of BioAtla stock on 4 March 2020 worth over $11,560. On average, Eddie trades about 71 units every 0 days since 2018. As of 4 March 2020 Eddie still owns at least 10,839 units of BioAtla stock.
You can see the complete history of Eddie Williams stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eddie Williams's mailing address?
Eddie's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, , NESS ZIONA,, L3, 7414003.
Insiders trading at BioAtla
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B..., and Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
What does BioAtla do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
What does BioAtla's logo look like?
Complete history of Eddie Williams stock trades at Catalyst Biosciences Inc, BiomX Inc, and BioAtla
BioAtla executives and stock owners
BioAtla executives and other stock owners filed with the SEC include:
-
Dr. Jay M. Short,
Co-Founder, CEO & Chairman -
Scott Andrew Smith,
Pres & Director -
Dr. Eric L. Sievers M.D.,
Chief Medical Officer -
Monica Sullivan,
Sr. VP of Intellectual Property & Contracts -
Christian Vasquez,
VP of Fin., Corp. Controller & Sec. -
Sheri Lydick,
Sr. VP of Commercial Strategy -
Dr. Eric L. Sievers,
Chief Medical Officer -
Dr. Cathy Chang Ph.D.,
Sr. VP of R&D -
Susie Melody,
VP of HR -
Lisa M. Pelton,
Accounting Mang. -
Philippe Martin,
Chief Clinical Devel. & Operations -
Richard A. Waldron,
Chief Financial Officer -
Lawrence Steinman,
-
Asset Management, Lp Chen B...,
-
Inc Pfizer Ventures (Us) Ll...,
-
Christian Vasquez,
See Remarks -
Jay M Phd Short,
Chief Executive Officer -
Richard A Waldron,
Chief Financial Officer -
Carolyn Anderson Short,
See Remarks -
Eric Sievers,
Chief Medical Officer -
Guy Levy,
-
Mary Ann Gray,
-
Susan Moran,
-
Parent Llc Himalaya,
10% owner -
Sylvia Mcbrinn,
-
Eddie Williams,